Hidradenocarcinoma in a Crohn's Patient on Ustekinumab: A Case Report

Overview

Journal SAGE Open Med Case Rep

Publisher Sage Publications

Specialty General Medicine

Date 2024 Jul 29

PMID 39071199

Authors

Madeline Alizadeh

Erin Zisman

Uni Wong

Affiliations

Soon will be listed here.

Abstract

Hidradenocarcinoma is a locally aggressive malignancy of the sweat glands, most commonly found on the head, neck, and upper body. Although rare, it has been seen in patients with hidradenitis supparativa, who have an increased risk of non-melanoma skin cancers. Ustekinumab, a biologic agent used to treat inflammatory bowel disease, has been associated with development of cancer in some patients. We present a case of a 36-year-old female with hidradenitis supparativa and Crohn's disease who developed hidradenocarcinoma in setting of ustekinumab use, demonstrating the need for further study of the relationship between biologic therapy and malignancy.

References

Gauerke S, Driscoll J . Hidradenocarcinomas: a brief review and future directions. Arch Pathol Lab Med. 2010; 134(5):781-5. DOI: 10.5858/134.5.781. View

de Lima A, Santos M, de Morais P, Rodrigues C . Hidradenocarcinoma. An Bras Dermatol. 2021; 96(2):251-253. PMC: 8007541. DOI: 10.1016/j.abd.2020.03.023. View

Jung J, Lee K, Kim Y, Chang S, Lee M, Choi J . Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2020; 156(8):844-853. PMC: 7254443. DOI: 10.1001/jamadermatol.2020.1422. View

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S . Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311(23):2406-13. DOI: 10.1001/jama.2014.5613. View

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F . Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017; 318(17):1679-1686. PMC: 5818785. DOI: 10.1001/jama.2017.16071. View

Guerrissi J, Quiroga J . Adnexal carcinomas of the head and neck. Indian J Plast Surg. 2009; 41(2):229-34. PMC: 2740523. DOI: 10.4103/0970-0358.44950. View

Ko C, Cochran A, Eng W, Binder S . Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006; 33(11):726-30. DOI: 10.1111/j.1600-0560.2006.00536.x. View

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C . North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019; 81(1):91-101. PMC: 9131892. DOI: 10.1016/j.jaad.2019.02.068. View

Singh H, Nugent Z, Demers A, Bernstein C . Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011; 141(5):1612-20. DOI: 10.1053/j.gastro.2011.07.039. View

10.

Hasan B, Tandon K, Miret R, Khan S, Riaz A, Gonzalez A . Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol. 2022; 37(6):1016-1021. DOI: 10.1111/jgh.15806. View

11.

Pinto-Almeida T, Torres T, Selores M . Multiple myeloma in a patient under ustekinumab--are they related?. Eur J Dermatol. 2013; 23(4):567-8. DOI: 10.1684/ejd.2013.2096. View

12.

Long M, Martin C, Pipkin C, Herfarth H, Sandler R, Kappelman M . Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012; 143(2):390-399.e1. PMC: 4065572. DOI: 10.1053/j.gastro.2012.05.004. View

13.

Gonzalez-Ramos J, Alonso-Pacheco M, Mayor-Ibarguren A, Herranz-Pinto P . Gastric mucosa-associated lymphoid tissue lymphoma in a patient with severe psoriasis receiving ustekinumab. Actas Dermosifiliogr. 2014; 106(4):326-7. DOI: 10.1016/j.ad.2014.05.010. View

14.

Young L, Czarnecki D . The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol. 2012; 53(1):57-60. DOI: 10.1111/j.1440-0960.2011.00853.x. View

15.

Soni A, Bansal N, Kaushal V, Chauhan A . Current management approach to hidradenocarcinoma: a comprehensive review of the literature. Ecancermedicalscience. 2015; 9:517. PMC: 4370612. DOI: 10.3332/ecancer.2015.517. View